Literature DB >> 10505094

Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.

L J Chang1, V Urlacher, T Iwakuma, Y Cui, J Zucali.   

Abstract

Lentiviruses infect both dividing and nondividing cells. In this study we characterized a lentiviral vector system consisting of a packaging vector (pHP) and a transducing vector (pTV) derived from a recombinant human immunodeficiency virus type 1 (HIV-1). In pHP, the long terminal repeats (LTRs), the 5' untranslated leader and portions of the env and nef genes were deleted. The leader sequence of pHP was substituted with a modified Rous sarcoma virus (RSV) 59 bp leader containing a mutated RSV gag AUG and a functional 5' splice site. The pHP construct was found to direct Gag-Pol synthesis as efficiently as wild-type HIV-1. The pTV construct contains sequences required for RNA packaging, reverse transcription and integration, but lacks viral genes. Co-transfection of pHP, pTV and a vesicular stomatitis virus G (VSV-G) envelope plasmid produced vectors at titers of 10(5)-10(6) transducing units per milliliter in 48 h. Replication-competent virus (RCV) was not detected when deletions were made in the env gene in pHP. The ability of this vector system to transduce dividing and nondividing cell in vitro and in vivo was also demonstrated. Compared with a Moloney murine leukemia virus (MLV) vector, the HP/TV vectors transduced human muscle-, kidney-, liver-derived cell lines and CD34+ primary hematopoietic progenitor cells more efficiently. Although the levels of the pTV transgene expression were high soon after transduction, the expression tended to decrease with time due either to the loss of proviral DNA or to the inactivation of promoter activity, which was found to be cell type-dependent. Analyses of extrachromosomal DNA showed that the unintegrated proviral DNA of lentiviral vectors survived much longer than that of the retroviral vectors. We demonstrate that the HP/TV vector is capable of high efficiency transduction and that long-term expression of lentiviral vectors is dependent on target cell type, the internal promoter and the transgene itself in the transducing vector.

Entities:  

Mesh:

Year:  1999        PMID: 10505094     DOI: 10.1038/sj.gt.3300895

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  114 in total

Review 1.  Real-time PCR in virology.

Authors:  Ian M Mackay; Katherine E Arden; Andreas Nitsche
Journal:  Nucleic Acids Res       Date:  2002-03-15       Impact factor: 16.971

2.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

3.  Pancreatic and duodenal homeobox gene 1 (Pdx1) down-regulates hepatic transcription factor 1 alpha (HNF1α) expression during reprogramming of human hepatic cells into insulin-producing cells.

Authors:  William Donelan; Shiwu Li; Hai Wang; Shun Lu; Chao Xie; Dongqi Tang; Lung-Ji Chang; Li-Jun Yang
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

4.  Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors.

Authors:  Makoto Yoshimitsu; Takeya Sato; Kesheng Tao; Jagdeep S Walia; Vanessa I Rasaiah; Gillian T Sleep; Gary J Murray; Armando G Poeppl; John Underwood; Lori West; Roscoe O Brady; Jeffrey A Medin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-18       Impact factor: 11.205

5.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration.

Authors:  Yasuhiro Koh; Xiaolin Wu; Andrea L Ferris; Kenneth A Matreyek; Steven J Smith; KyeongEun Lee; Vineet N KewalRamani; Stephen H Hughes; Alan Engelman
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.

Authors:  Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

10.  Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid.

Authors:  Arne Schneidewind; Mark A Brockman; John Sidney; Yaoyu E Wang; Huabiao Chen; Todd J Suscovich; Bin Li; Rahma I Adam; Rachel L Allgaier; Bianca R Mothé; Thomas Kuntzen; Cesar Oniangue-Ndza; Alicja Trocha; Xu G Yu; Christian Brander; Alessandro Sette; Bruce D Walker; Todd M Allen
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.